Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca’s MEK Inhibitor Boosts PFS, But Misses Overall Survival Endpoint In Lung Trial

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

MEK inhibitor selumetinib improves progression-free survival in KRAS mutation-positive metastatic non-small cell lung cancer, hitting secondary endpoints. But the drug missed the overall survival primary endpoint.


Related Content

AstraZeneca Oncology Focused On Combinations, But Differentiation Will Be Key
Over A Decade In The Making, MEK Inhibitors Break Through In Melanoma


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts